Idelalisib D5
Code | Size | Price |
---|
TAR-T11610-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11610-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Idelalisib D5 is a deuterium-labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor.
CAS:
1830330-31-8
Formula:
C22H18FN7O
Molecular Weight:
420.45
Pathway:
PI3K/Akt/mTOR signaling
Purity:
0.98
SMILES:
[C@H](NC1=C2C(N=CN2)=NC=N1)(CC)C=3N(C(=O)C=4C(N3)=CC=CC4F)C5=C(C(=C(C(=C5[2H])[2H])[2H])[2H])[2H]
Target:
PI3K
References
Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117(2), 591-594.